ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
60,916.52
0.20%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Nurix Therapeutics Inc (NRIX)

  7. Nurix Therapeutics Inc (NRIX) News

Nurix Therapeutics (NRIX)

Nurix Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NRIX
DateTimeSourceHeadlineSymbolCompany
07/05/202412:00GlobeNewswire Inc.Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare ConferenceNASDAQ:NRIXNurix Therapeutics Inc
16/04/202423:21GlobeNewswire Inc.Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesNASDAQ:NRIXNurix Therapeutics Inc
12/04/202404:38GlobeNewswire Inc.Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
11/04/202421:00GlobeNewswire Inc.Nurix Therapeutics Announces Proposed Public OfferingNASDAQ:NRIXNurix Therapeutics Inc
10/04/202412:00GlobeNewswire Inc.Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
09/04/202418:15GlobeNewswire Inc.Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell MalignanciesNASDAQ:NRIXNurix Therapeutics Inc
09/04/202412:00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6NASDAQ:NRIXNurix Therapeutics Inc
03/04/202412:00GlobeNewswire Inc.Nurix Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:NRIXNurix Therapeutics Inc
02/04/202412:00GlobeNewswire Inc.Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead SciencesNASDAQ:NRIXNurix Therapeutics Inc
25/03/202411:00GlobeNewswire Inc.Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)NASDAQ:NRIXNurix Therapeutics Inc
20/03/202413:40GlobeNewswire Inc.Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) MeetingNASDAQ:NRIXNurix Therapeutics Inc
11/03/202411:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
11/03/202411:00GlobeNewswire Inc.Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 TrialNASDAQ:NRIXNurix Therapeutics Inc
06/03/202421:00GlobeNewswire Inc.Nurix Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:NRIXNurix Therapeutics Inc
05/03/202421:30GlobeNewswire Inc.Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual MeetingNASDAQ:NRIXNurix Therapeutics Inc
17/02/202400:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
16/02/202421:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NRIXNurix Therapeutics Inc
15/02/202421:51Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NRIXNurix Therapeutics Inc
15/02/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NRIXNurix Therapeutics Inc
15/02/202421:00GlobeNewswire Inc.Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:NRIXNurix Therapeutics Inc
15/02/202412:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
15/02/202412:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
15/02/202412:23Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
14/02/202413:51Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NRIXNurix Therapeutics Inc
01/02/202421:01GlobeNewswire Inc.Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 DegraderNASDAQ:NRIXNurix Therapeutics Inc
30/01/202423:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
30/01/202423:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
30/01/202423:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NRIXNurix Therapeutics Inc
29/01/202421:00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NRIXNurix Therapeutics Inc
16/01/202421:48Dow Jones NewsNurix Therapeutics Gets FDA Fast-Track Designation for NX-5948NASDAQ:NRIXNurix Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NRIX

Your Recent History

NYSE
ASD
American Standard
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved